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A B S T R A C T
Objectives: This study assessed the cost-effectiveness and health-care budget impact of
sacral neuromodulation (SNM) in refractory idiopathic OAB-wet patients in Spain.
Methods: A 10-year Markov analytic model was developed to estimate quality-adjusted life-
years (QALYs) gained and incontinence episode avoided associatedwith SNM therapy compared
with botulinumneurotoxin A (BoNT-A) or continued optimizedmedical treatment (OMT).
Results: At10years, the cumulative costs of SNM,BoNT-A, andOMTwere €29,166, €29,458, and
€29,370, respectively, whereas the QALYs for SNM, BoNT-A, and OMT are 6.89, 6.38, and 5.12,
respectively. Consequently, incremental cost-effectiveness ratios (ICERs) for SNMdemonstrate
that although the initial costs for SNM are higher than those for the other treatments, decreas-
ing follow-up costs coupledwith consistently greater effectiveness in the long termmake SNM
the economically dominant option at 10 years. Sensitivity analyses suggest that 99.7% and
99.9% (for SNMvs. BoNT-A andOMT, respectively) of the 1000Monte Carlo iterations fall within
the €30,000 cost-effectiveness threshold, considered to be acceptable in Spain. The 10-year
incremental cost per incontinence episode avoided for SNM alsomakes this therapy the dom-
inant option compared to BoNT-A or OMT. Additionally, the estimated budget impact of the
gradually increased referral for SNM for the management of OAB patients in Spain is small.
Conclusions: As a treatment option for refractory idiopathic OAB, at 10 years, SNMprovides
a considerable possibility of symptom and quality-of-life improvement and is cost-effective
compared to BoNT-A or continued OMT.
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Epidemiology and burden
Overactive bladder (OAB) is a chronic condition characterized
by urinary symptoms of urgency and frequency and with (i.e.,
OAB wet) or without urinary urge incontinence [1]. These
symptoms can be distressing and socially disruptive to pa-
tients, causing significant impairment to their health-related
quality of life (HRQoL) [2]. In Spain, the prevalence of symp-
toms suggestive of OAB is estimated to be 19.9% in the adult
population of age 40 years and older and particularly high in
women (25.6%) [3]. OAB-related direct costs incurred by the
Spanish health-care system are estimated to exceed €700mil-
lion, and direct annual per-patient costs are estimated to be as
high as €550 per patient; the largest proportion of these costs
are attributed to the use of incontinence pads [4].
OAB management pathways
In line with international (International Consultation on Incon-
tinence) treatment guidelines, first-linemanagement for OAB in
Spain involves antimuscarinic agents [5]. Clinical trials show
some degree of improvement with antimuscarinic agents; how-
ever, a high proportion of patients (25%–40%) remain refractory
to treatment [6]. Although many refractory patients cease drug
reatment [7], a proportion continues with drugs in combination
with pad use for several years, undergoing numerous drug
switches [8] before eventually embarking on alternative treatment
strategies. Sacral neuromodulation (SNM) therapy and botulinum
neurotoxin A (BoNT-A) are the less invasive treatment options for
patientswho are refractory to antimuscarinic agents.
Clinical benefits of SNM therapy are obtained from the elec-
trical impulses generated by an implanted neurostimulator and
delivered via a conducting electrode to one of the sacral nerves
involved in control of urinary function. Compared to other mo-
dalities such as augmentation cystoplasty, implantation of the
neurostimulator is a minimally invasive procedure that is per-
formed after a successful test to screen suitable patients. TheFig. 1 – Modeltest is an effective predictor of success before the fully reversible
surgical implantation. Results of short- and long-term clinical
studies of SNM demonstrate high rates of clinical success, de-
fined as a significant reduction in voiding-related symptoms,
voided volume, and thenumber of padsuseddaily and improve-
ment in health-related quality of life (HRQoL) [9–12].
Injectionof thebladderwallwithBoNT-A, althoughcurrently
not licensed for use for the idiopathic OAB indication Europe, is
often used to treat refractory idiopathic OAB in Spain. Multiple
injections of minute doses in the bladder wall reduce neuronal
activity and decrease detrusor pressure. Repeat administration,
however, is required tomaintain symptomatic improvement as
the effect of BoNT-Awears off over time [13]. Although results of
short-term clinical trials demonstrate the effectiveness of
BoNT-A, further studies are needed to demonstrate the long-
term efficacy and safety of repeat injections.
Objectives
Given thatOAB isachronic condition,ourobjectivewas toassess
the long-termcost-effectiveness of treatmentwith SNM therapy
in refractory idiopathic OAB-wet patients, from the Spanish Na-
tional Health Service (NHS) perspective, compared to repeat
BoNT-A injections or optimized medical treatment (OMT) con-
sisting of continued drug and pad use. The potential budget im-
pact to theSpanishNHS for providingSNMtoan increasednum-
ber of Spanish OAB patients was also measured.
Materials and methods
Study design
The cost-effectiveness analysis (CEA) was evaluated using a
decision analytic model constructed and analyzed with Mi-
crosoft Excel 2003 spreadsheet software (with Visual Basic
programming), which is a widely used and transparent tool to
develop economic models [14].
The model, which reflected international OAB management
guidelines [15,16], simulated a hypothetical cohort of OAB pa-diagram.
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221V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 1 9 – 2 2 8tients through three alternative treatment pathways (Fig. 1)
over a 10-year time frame: 1) SNM therapy involving test
and permanent implant, 2) BoNT-A injections, or 3) contin-
ued OMT (drugs and pad use). A Markov approach was used
to analyze the long-term prognosis of refractory idiopathic
OAB patients after failure with first-line OMT. For chronic
diseases such as OAB, Markov models offer advanced deci-
sion tools to study health states that recur and change over
a long period of time, particularly when they cannot be cap-
tured within clinical studies; thus enabling the simulation
of health outcomes and costs using long-term data gathered
from multiple sources.
The 10-year model was divided into 12-month cycles. Dur-
ing each cycle, patients remained in the same treatment as
the previous cycle unless the treatment outcome (defined as
success or failure) was a failure. When a failure occurred, pa-
tients switched to another treatment according to the treat-
ment transition rates specified by an expert panel (Table 1).
After 10 cycles, cumulative costs, effectiveness measured as
quality-adjusted life years (QALYs), and the number of incon-
tinence episodes estimated by ascribing a given number of
incontinence episodes to success and failure [11] were calcu-
lated. These estimates were then used to derive an incremen-
tal cost-effectiveness ratio (ICER), the ultimate measure of in-
terest in a CEA, which is defined as the ratio of the difference
in costs and the difference in outcomes for one intervention
compared to another. The ICERs in the current study are
expressed as the incremental cost per QALY gained and in-
cremental cost per incontinence episode avoided at 10 years
for SNM compared to the other treatment pathways. In line
with current recommendations for CEA conducted in Euro-
pean settings, a discount rate of 3% per annum was applied
to the ICER estimates to account for the current value of the
future stream of costs and effectiveness [17]. An expert
panel of five experienced urologists from four Spanish hos-
pitals developed assumptions of treatment pathways; pro-
vided rates of resource use, treatment transitions, and ad-
verse events; and validated effectiveness outcomes. The
Table 1 – Treatment transition rates*.
After failure of
SNM test and permanen
SNM test and permanent implant —
BoNT-A 79
OMT —
BoNT-A, botulinum neurotoxin A; OMT, optimized medical treatmen
* Proportion of patients receiving the next available treatment follow
Table 2 – Treatment outcomes.
Treatment 1 year, % 2 years, % 3 years, %
SNM 90 86 82
BoNT-A 80 74 68
OMT 4 4 4BoNT-A, botulinum neurotoxin A; OMT, optimized medical treatment; SNpanel was consulted via two focus group meetings and
structured interviews.
The model also facilitated the budget impact analysis,
which evaluated the direct cost impact on the Spanish NHS in
four consecutive years if the number of women treated with
SNM therapy increased.
Treatment outcomes
The outcomes of OAB in the treatment arms of themodelwere
classified as success (50% improvement in incontinence
symptoms) or failure (50% improvement in incontinence
symptoms).
Treatment outcomes (Table 2) were primarily based on a
literature review of evidence published within databases
including Cochrane, Centre for Reviews and Dissemination,
PubMed, the CEA Registry, and the Spanish Medical Index.
The search strategy identified studies that were published in
English or Spanish that analyzed OAB clinical or HRQoL out-
comes or resource utilization and in relation to SNM and the
comparators in the treatment of OAB.Whenpublished evidence
was lacking, expert panel input was the source for model data.
In the SNM arm of themodel, treatment outcomes for the
definitive implant of SNM up to 5 years were based on com-
bined clinical trial data of two implantation methods [11–
3,18]. It was assumed that patients first undergo screening
or an average duration of 3.2 weeks (based on expert opin-
on), resulting in a positive response rate of 80% [18,19].
Thus, the first year treatment success rate of 90% (Table 2) is
relevant to the proportion showing a positive response to
screening.
The clinical outcomes for BoNT-A in the first year were
based on results observed in one-injection cycle trials in
idiopathic OAB [12,20]. The expert panel provided addi-
tional input on treatment patterns, as follows: 1) Repeat
injections at a 100-U dose were administered every 9
months for BoNT-A responders (in 20% of patients in whom
treatment failed in the first cycle, the dose was increased to
Next treatment Line
lant, % BoNT-A, % Cystoplasty, % OMT, %
77 5 18
— 5 16
— — 100
M, sacral neuromodulation.
failure of treatment as listed in first left-hand-side column.
years, % 5 years, % 7 years, % 10 years, %
78 75 75 75
63 59 54 50
4 4 4 4t imp
t; SN4M, sacral neuromodulation.
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estimated by applying a yearly treatment dropout rate of
7.5% to account for the treatment efficacy waning over time,
Table 3 – Treatment costs.
Treatment
Preprocedure
(e.g., lab tests,
radiography), €
Procedure (includin
device or drug), €
SNM test 558 2781
SNM 102 9734
BoNT-A (costs repeated
every 9 months)
572 1192
OMT — First-line drug cost:
€153
Second-line drug cost:
€189
Third-line drug cost:
€20
Fourth-line drug cost:
€51
Cystoplasty 736 (includes
cystoscopy)
2783
Major adverse
SNM Reoperation: 8%a
Lead- or IPG-related issues: 4%–5%a
Surgical site/device infection: 3%b
BoNT-A Partial urinary retention: 45%c
Acute urinary retention: 23%d
Dysuria: 24%e
Urinary tract infection: 24%f
OMT Urinary tract infection: 11.5%g
Xerostomia: 16%h
Risk of fracture: 8%i
Constipation: 7%h
Cystoplasty Urinary tract infection: 24%j
Calculus formation: 24%k
Bladder perforation: 5%l
BoNT-A, botulinum neurotoxin A; IPG, implantable pulse generator;
a Kessler TM, Buchser E, Meyer S, et al. Sacral neuromodulation for r
in Switzerland. Eur Urol 2007;51(5):1357–63.
b van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Resu
outcomes of a prospective, worldwide clinical study. J Urol 2007;17
c Brubaker L, Richter HE, Visco A, et al. Pelvic Floor Disorders Netw
injection. J Urol 2008;180(1):217–22.
d Werner M, Kuschel S, Schmid DM, Schuessler D. Efficacy of botuli
incontinence: long-term results of a prospective nonrandomized s
e Kuo HC. Comparison of effectiveness of detrusor, suburothelial a
overactivity. J Urol 2007;178:1359–63.
f Sahai A, Khan Ms, Dasgupta P; the GKT Botulinum Study Group. E
results from a single center, randomized, double-blind, placebo con
g Klotz T, Brüggenjürgen B, Burkart M, Resch A. The economic costs
h Staskin D, Sand P, Zinner N, Dmochowski R, for the Trospium Study
treatment of overactive bladder: results from a multicenter phase
i Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: doe
Research Group. J Am Geriatr Soc 2000;48:721–5.
j McDougal WS. Metabolic complications of urinary intestinal divers
k Blyth B, Ewalt DH, Duckkett JW, Snyder HM III. Lithogenic properti
l Bauer SB, Hendren WH, Kozakewich H, et al. Perforation of the augmentdiscontinuation due to adverse events, or a search for a
definitive solution as observed in patients with detrusor
overactivity [21].
Costs
dverse events
(per annum
costs), €
Follow-up (per 3 months) Follow-up after
treatment
failure, €Up to first
3 months, €
After first
3 months, €
— 94 867
436 166 98 937
132 500 233 1554
302 707 707 732
415 4249 415 8536
ts considered
optimized medical treatment; SNM, sacral neuromodulation.
tory lower urinary tract dysfunction: results of a nationwide registry
f sacral neuromodulation therapy for urinary voiding dysfunction:
029–34.
Refractory idiopathic urge urinary incontinence and botulinum A
toxin A in the treatment of female idiopathic detrusor overactivity
Eur Urol Suppl 2006;5(11):685–90.
adder base injections of botulinum toxin A for idiopathic detrusor
y of botulinum toxin-A for treating idiopathic detrusor overactivity:
ed trial. J Urol 2007;177:2231–6.
eractive bladder in Germany. Eur Urol 2007;51(6):1654–62.
p. Once daily trospium chloride is effective andwell tolerated for the
l. J Urol 2007;178:978–83.
ncrease risk for falls and fractures? Study of Osteoporotic Fractures
Urol 1992;147(5):1199–208.
enterocystoplasty. J Urol 1992;148:575.g A
even
OMT,
efrac
lts o
8(5):2
ork.
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tudy.
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es ofed bladder. J Urol 1992;148:699–703.
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ment data in refractory patients who continued treatment [9];
his rate was maintained throughout the period. Augmenta-
ion cystoplasty (i.e., surgery to increase bladder capacity) was
ncluded as a treatment option after failure of SNMor BoNT-A,
s shown in Fig. 1).
Qalys
To measure the impairment to patient HRQoL [2] due to OAB,
QALY weights were assigned to the health outcomes of treat-
ment success or failure. QALYs are a measure of the length of
Table 4 – Cost-effectiveness analyses.
Treatment Improvement, % Tota
5
SNM 72.1 1
BoNT-A 68.6 1
OMT 0.0 1
Incremental: SNM vs. BoNT-A year 5
Incremental: SNM vs. OMT year 5
7
SNM 68.8
BoNT-A 62.9
OMT 0.0 2
Incremental: SNM vs. BoNT-A year 7
Incremental: SNM vs. OMT year 7
10
SNM 62.1 2
BoNT-A 55.2 2
OMT 0.0 2
Incremental: SNM vs. BoNT-A year 10
Incremental: SNM vs. OMT year 10
BoNT-A, botulinum neurotoxin A; ICER, incremental cost-effective
life-year; SNM, sacral neuromodulation.Fig. 2 – CE acceptability curvlife adjusted for HRQoL related to a disorder, in addition to
health benefits associatedwith treatment. Thus, 1 year of per-
fect health is equivalent to 1.0 QALY. The QALY weights ap-
plied to the current model were derived from the literature,
because none of the SNM trials directly measured utilities as-
sociated with OAB outcomes. Thus, the QALY weights in the
current analysis were defined as 0.793 for treatment success
(continence) and 0.573 for treatment failure (incontinence),
as estimated from a synthesis of Basque general population
utilities [22] and from Wu et al. [23]. Although we believe
that the same sources for the QALYs would have been better
for model validity, the utility values from Wu et al., which
patient
, €
QALYs ICER (cost/
QALYs
gained), €
Episodes ICER (costs/
episode
avoided), €
3.69 9561
3.45 9790
2.75 16,529
0.24 3775 229 4.02
0.94 3412 6968 0.46
.019 5.03 12,976
.597 4.68 13,389
3.74 22,486
0.35 9830 413 8.29
1.29 3433 9509 0.47
s
6.89 17,765
6.38 18,498
5.12 30,787
0.51 Dominant 733 Dominant
1.77 Dominant 13,021 Dominant
ratio; OMT, optimized medical treatment; QALY, quality-adjustedl per-
costs
years
9,156
8,235
5,932
921
3223
years
26
22
1,593
3422
4426
year
9,166
9,458
9,370
292
204
nesse for SNM versus BoNT.
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nence, were considered to be very high for Spain, as sug-
gested by the Basque general population utility of 0.793.
Thus, we applied the net disutility of 0.221 of Wu et al.
associated with moving from a continent to an incontinent
health state to the Basque general population utility scores
to obtain the respective utilities for the treatment outcomes
in the model; these were deemed to provide conservative
estimates of QALYs after OAB treatment. Cumulative QALYs
were then derived for each treatment arm at a given time-
frame of analysis.
Cost inputs
Because the perspective of the model was from the Spanish
NHS, the analyses considered direct health-care costs only,
and these were expressed in 2008 Euro values. Costs com-
prised health-care resources used at treatment initiation (pre-
procedure costs), during treatment (procedure and drug
costs), during follow-up, for adverse events, and after treat-
ment failure (Table 3). Estimates of the units of health-care
Fig. 3 – CE acceptability
Table 5 – Incontinence disutility sensitivity analysis.
Disutility value
SNM vs. BoNT-A
5 years 7 years
0.293 2834 7381
0.243 3418 8900
0.220 3775 9830
0.193 4303 11,206
0.143 5807 15,124
0.093 8930 23,255BoNT-A, botulinumneurotoxinA; ICER, incremental cost-effectiveness ratiresources for OMT were obtained from published sources
[4,24], whereas other estimates were provided by expert opin-
ion. Unit costs were obtained from the 2008 e-Salud Spanish
health-care cost database, and the SpanishMinistry of Health.
SNM device costs were based on InterStim and provided by
Medtronic. SNM costs also included device and implant costs
and, due to device longevity, costs of one neurostimulator bat-
tery replacement at year 7. BoNT-A drug costs were based on a
100-U dose of Botox.
Sensitivity analyses
Probabilistic sensitivity analyses, accounting for the inherent
uncertainty in the parameters of the economic evaluation,
were conducted via Monte Carlo simulations with 1000 itera-
tions for each treatment. The main uncertainty stems from
clinical trial heterogeneity in the definition and measures of
symptom improvement, length of follow-up, patient popula-
tions, and the lack of long-term data, which thus required
treatment outcome assumptions beyond 5 years for SNM, be-
yond 1 year for BoNT-A, and beyond 6months for OMT. Hence,
e for SNM versus OMT.
ICER, €
SNM vs. OMT
ars 5 years 7 years 10 years
inant 2562 2578 Dominant
inant 3089 3109 Dominant
inant 3412 3433 Dominant
inant 3889 3914 Dominant
inant 5249 5282 Dominant
inant 8071 8122 Dominantcurv10 ye
Dom
Dom
Dom
Dom
Dom
Domo; OMT, optimizedmedical treatment; SNM, sacral neuromodulation.
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225V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 1 9 – 2 2 8fixed probability distributions were selected (log-normal dis-
tribution for costs, normal distribution for resource use, and
beta/Dirichlet distribution for probabilities), and the parame-
ters of each distribution were estimated using the SD and 10%
increment/decrement of the mean of primary data. Data that
were estimated or obtained via expert opinion underwent
variation ranging from 15% to 200%. Two separate determin-
istic sensitivity analyses were also performed. The first anal-
ysis examined the effect of variation in treatment parameters
based on a recent study of a 200-U BoNT-A dose; this included
reinjection every 14 months, an 8% dropout rate, adverse
events including 43% self-catheterization and 15% acute uri-
nary retention [25]. A further sensitivity analysis examined
he effect of a variation to the disutility value of 0.22 applied to
he estimation of QALYs related to OAB treatment outcomes.
Table 6 – Budget impact analyses.
Target population and in
Population (women  45 years of age)a
Prevalence of OAB in Spain (in women  45 years of age), % (no.)
OAB with urge incontinence
Idiopathic OAB wet
Diagnosed
Treated
In whom OMT failed
Target patient populatio
OMT
Patient treatment rates by therapy, % 89.7
Annual incidence of OAB
1 year
Patients with OAB who fail first-line OMT 31,399
Patients with current SNM treatment rates
(5.7% based on expert opinion)
OMT 28,165
Cystoplasty 94
SNM 1036
BoNT-A 2104
Patients with increased SNM treatment rates
(11.4% based on expert opinion)
OMT 28,114
Cystoplasty 93
SNM 1095
BoNT-A 2098
Budget impact with current SNM treatment
rates, €
15,154,472
Budget impact with increased SNM treatment
rates, €
15,398,301
Net impact, € 243,829
% Net impact 0.2
BoNT-A, botulinum neurotoxin A; OAB, overactive bladder; OMT, opt
a Spanish Statistics Institute. Last population analysis, 2008.
b Martínez Agulló E, Ruiz Cerdá JL, Gómez Pérez L, et al; Grupo de E
hiperactiva en la población española: resultados del estudio EPICC [P
population: results of the EPICC study]. Actas Urol Esp 2009;33(2):15
c Castro D, Espuña M, Prieto M, Badia X. Prevalencia de vejiga hipera
Spain: a population-based study]. Arch Esp Urol 2005;58(2):131–8.
d Wein AJ. Diagnosis and treatment of the overactive bladder. Urolo* Expert panel.Results
Cost-effectiveness
Results of the CEA (Table 4) indicate that, from a medium-term
perspective, ICER estimates for SNM are €3775 compared to
oNT-Aand €3412 compared toOMTat 5years,whereas ICERsat
years (which accounts for an SNM generator replacement) are
9830 and €3433 compared to BoNT-A and OMT, respectively.
hese results suggest cost-effectiveness forSNMin themedium-
erm given that the ICERs are well within the €30,000 cost-effec-
iveness threshold, which is deemed as efficient in Spain [26].
dditionally, at 10 years, the cumulative costs of SNM, BoNT-A,
ndOMTare €29,166, €29,458, and €29,370, respectively, with cu-
ental potential of SNM
10,309,538
17.37b (1,790,338)
68c (1,217,430)
90c (1,095,687)
52c (569,757)
16.7c (95,149)
33d (31,399)
1,399: current scenario*
Cystoplasty SNM BoNT-A
0.3 3.3 6.7
Budget impact
2%
2 years 3 years 4 years
32,059 32,732 33,419
28,704 29,250 29,803
95 95 95
1118 1207 1302
2142 2180 2219
28,593 29,067 29,533
91 90 88
1246 1417 1612
2129 2158 2187
18,517,065 20,424,484 122,305,077
19,889,765 21,872,397 123,828,982
1,372,700 1,447,913 1,523,906
1.16 1.20 1.25
d medical treatment; SNM, sacral neuromodulation.
o Cooperativo EPICC. Prevalencia de incontinencia urinaria y vejiga
lence of urinary incontinence and hyperactive bladder in the Spanish
.
en España: estudio poblacional [Prevalence of overactive bladder in
3;62(5 Suppl 2):20–7.crem
n  3
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226 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 1 9 – 2 2 8mulative QALYs of 6.89, 6.38, and 5.12. Thus, the relative cost
savings for SNM, coupledwith its enhancedoutcomescompared
to either treatment, demonstrate that SNM is the economically
dominant treatment option in a 10-year time frame. Further-
more, ICERs for incontinence episode avoided at 10 years also
demonstrate economic dominance for SNM compared to
BoNT-A and OMT.
Sensitivity analyses
The 1000 incremental CEA results obtained in the probabilistic
sensitivity analyses are plotted in acceptability curves of SNM
versus the comparative treatment (Figs. 2 and 3). These rep-
resent the probabilities that the treatment is cost-effective
at different threshold values of cost-effectiveness, based on
the CEA conducted. Given an acceptable cost-effectiveness
threshold of €30,000 in Spain [26], the analyses suggest that
99.7% of the 1000 simulations fall below the threshold when
comparing SNM to BoNT-A (Fig. 2). When comparing SNM to
OMT, 99.9% of the simulations fall within the acceptable
threshold (Fig. 3).
Similarly, deterministic sensitivity analyses, applying
the different BoNT-A treatment parameters from a recent
trial [25] also demonstrate the robustness of the inputs, ob-
taining similar results of dominance at 10 years and cost-
effectiveness at 5- and 7-year time frames. When the sen-
sitivity analysis considered net disutility values presented
in the other studies of incontinence symptom impact
[27,28], the cost-effectiveness of SNM compared to BoNT-A
and OMT remained (Table 5.)
Budget impact
An estimation of the target population of female adult pa-
tients older than 45 years of age for the budget impact analysis
is shown in Table 6. The estimated target population suitable
for a test trialwith SNM is 31,000 patients.With an annual OAB
incidence rate of 2%, the estimated net impact of increasing
the treatment rate of SNM by 11.4% in the current manage-
ment of OAB patients in Spain seems to be small, representing
an increment of 0.2% to 1.25% only in total costs, respectively,
from year 1 to year 4 (Table 6 and Fig. 4).
 €0
 €20,000,000
 €40,000,000
 €60,000,000
 €80,000,000
 €100,000,000
 €120,000,000
 €140,000,000
1 year 2 year
WITHOUT INTERSTIM®ithout S MFig. 4 – Potential budget impact of introducinDiscussion
Idiopathic OAB causes appreciable burden to patients’ HRQoL
and results in significant costs related to pad use and urinary
tract infections [2,4]. Moreover, health-care practice indicates
that a high number of drug refractory patients continue with
several oralmedication switches despite experiencing no last-
ing improvement. Given the availability of multiple OAB ther-
apies that can improve patient symptoms, it is necessary to
assess their clinical and economic value to aid health-care
decisionmaking in the selection of treatment. Because OAB is
a chronic condition, any appropriate assessment of treatment
must reflect a long-term perspective.
Currently, two publications compare the cost-effective-
ness of BoNT-A to that of anticholinergic agents [23] and to
SNM [29], which is only present in a 2-year time frame in the
US setting. Other analyses [30] comparing BoNT-A, SNM, and
augmentation cystoplasty only compared 3-year direct treat-
ment costs. These perspectives are limited because they do
not consider treatment outcomes and other longer term cost
drivers pertaining to treatment failure and adverse events.
SNM therapy has existed since 1994 for refractory OAB [11].
The treatment is now included in international (ICI) and Euro-
pean (European Association of Urology) guidelines for idio-
pathic OAB before invasive surgical procedures [15,16] Until
now, the combined clinical and economic value of this tech-
nology has not been assessed. The results of the current 10-
year study confirm that SNM in Spain is the superior treat-
ment option after first-line medical management fails. The
relatively higher initial costs of SNMare offset by the favorable
longer term outcomes of symptom and HRQoL improvements
and lower annual follow-up costs compared to both BoNT-A
and OMT, which require repeat treatment. Apart from yearly
follow-up outpatient visits, treatment reintervention is only
required every 7 years to replace the depleted neurostimulator
battery (cost included in this study). Furthermore, the health-
care budget impact of increasing the referral of eligible OAB
patients to SNM in Spain seems to be small and affordable in
the subsequent 4 years.
Although medical management is the first-line treatment
and is not a relevant direct comparator to SNM, the compari-
3 years 4 years
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OAB patients in Spain can remain on drug treatment indefi-
nitely (OMT).
Although BoNT-A is not commercially licensed for the
treatment of OAB patients, it is routinely used in clinical
practice. Several treatments are required during a patient’s
life time; however, the long-term efficacy and safety trial
evidence is limited beyond the administration of the first
injection. The lack of a standard treatment protocol among
practitioners poses additional challenges [31] to measuring
cost- effectiveness from a national perspective. In addition
to a base-case treatment protocol provided by expert opin-
ion (100-U dose, reinjection every 9 months, 7.5% dropout
rate), a deterministic sensitivity analysis was performed
with a different set of variables (200-U dose, reinjection ev-
ery 14 months, 8% dropout rate). The cost-effectiveness re-
sults were similar. Conservative assumptions made in this
CEA to estimate the mid- to long-term BoNT-A efficacy
mainly account for the patient dropout rate due to reduced
efficacy, intolerable adverse events, or the search for a de-
finitive solution.
For SNM, recent technological changes in the screening and
implant methods have increased positive screening results [32].
Because there are no long-term clinical data on new implanta-
tion methods, the clinical data used to determine SNM treat-
ment effectiveness in the long-term were based on the former
implantation method [18] with evidence up to 5 years.
A primary limitation of this CEA is the lack of direct com-
arative data and long-term evidence from clinical studies
omparing the alternative treatments. This subjects the
odel to uncertainty because treatment outcome assump-
ions are based on different sources and levels of evidence.
lthough in the future, comparative and longer term clinical
rials showing the efficacy, safety, and impact on HRQoL of
NM and BoNT-A may provide more reliable data to measure
he cost-effectiveness of SNM, there is a pressing need to sub-
tantiate the long-term cost-effectiveness for mainstream re-
ractory OAB treatments such as SNM and BoNT-A (which is
eing widely used before its approval for use in idiopathic
AB) with the available evidence base [33] and confirm these
results with direct comparative evidence when it is available.
These CEA data are also pertinent to the Spanish NHS because
the extensive use of BoNT-A in idiopathic OAB patients pre-
senting to their clinical services is nowadays a reality despite
the lack of an indication for this use [34]. This was the moti-
vation for the current study. Furthermore, when data limita-
tions such as these do exist, the application of evidence syn-
thesis for indirect comparisons is recognized to fulfill the
established international and regional frameworks for rigor-
ous analytical methodology to support clinical decision mak-
ing [35,36]. Nonetheless, the robust sensitivity analysis ap-
plied to handle all the uncertainties of the model indicated a
high probability of SNM cost-effectiveness.
Conclusions
As a treatment option for refractory idiopathic OAB patients,
SNM provides a considerable possibility of symptom andHRQoL improvement and is cost-effective compared to
BoNT-A or continued OMT.
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